In Memoriam

LONDON, ONTARIO August 20, 2019 -- It is with great sadness that OB Pharmaceutical announces the sudden death of its cofounder and CSO, Dr. Michael Poulter, after a short illness. Dr. Poulter received his undergraduate degree in Pharmacology from the University of British Columbia. He continued his studies at McGill University where he received a PhD in Pharmacology and conducted his postgraduate research at the NIH in Washington DC and at the Université Louis Pasteur, Strasbourg, France. Dr. Poulter returned to Canada in 1995, taking positions first at the National Research Council in Ottawa and subsequently at the Institute for Neuroscience at Carleton University, becoming head of the Institute in 2003. In 2006 he relocated to London, ON, taking a position as Scientist at the Robarts Research Institute and as Professor in the Department of Physiology and Pharmacology at the University of Western Ontario. He dedicated his life to epilepsy research and donated his time to Epilepsy Canada, as a Board Member and a Member of the Scientific Research Committee, with a mission to find a cure and enhance other research efforts across Canada. Moreover, he was an avid skier and advanced sailor, a great bass player and an excellent cook. He cofounded OB Pharmaceuticals with operations starting in the fall of 2014 and led the preclinical program through lead discovery, creating novel in vivo models to elucidate the nature and control of seizures arising from traumatic brain injury. "Mike has been a dear friend and colleague of mine in science and business for 30 years." remarked Dr. Larry Mahan, CEO of OB Pharmaceuticals. "We will honor his memory by intensifying our efforts to bring our compounds into the clinic and ultimately as therapies for those unmet medical needs in patients who suffer these debilitating disorders." The company has initiated steps to fill the CSO position.

About OB Pharmaceuticals

OB Pharmaceuticals is an early stage biopharmaceutical company dedicated to improving the lives of individuals through the development of first-in-class therapeutics for more effective prevention and management of epilepsy and other related seizure disorders.